People: Theratechnologies Inc (TH.TO)

TH.TO on Toronto Stock Exchange

4.74CAD
9 Feb 2010
Price Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.74
Open
--
Day's High
$4.77
Day's Low
$4.65
Volume
77,828
Avg. Vol
176,161
52-wk High
$5.50
52-wk Low
$1.18

view people for:

Summary

Name Age Since Current Position
Pommier, Paul 2007 Chairman of the Board
Rosconi, Yves 2004 President, Chief Executive Officer, Director
Tanguay, Luc 2004 Chiref Financial Officer, Senior Executive Vice President, Director
Colussi, Marie-Noel 2002 Vice President - Finance
Lafond, Jocelyn Vice President - Legal Affairs,Corporate Secretary
Gilpin, Andrea 2007 Vice President - Investor Relations and Communications
Perazzelli, Pierre Vice President - Pharmaceutical Development
Ortega, Martine 2007 Vice President - Compliance and Regulatory Affairs
Marsolais, Christian 2007 Vice President - Clinical Research and Medical Affairs
Peri, Krishna 2004 Vice President - Research
Desrochers, Chantal 2005 Vice President - Business Development and Commercialisation
De Grandpre, A. Jean 2007 Corporate Director
Talon, Jean-Denis 66 2001 Director
Cloutier, Gilles 56 2003 Corporate Director
Goyer, Robert 2005 Director
Reculeau, Bernard 58 2005 Director
Lacoste, Gerald 2006 Corporate Director
» Insider Trading

Biographies

Name Description
Pommier, Paul Mr. Paul Pommier, MBA is Chairman of the Board of Theratechnologies, Inc. Mr. Paul Pommier worked for more than twenty five years at National Bank Financial, his last position being Senior Executive Vice President, Corporate and Government Finance. Throughout his career, he oversaw public and private financings, mergers and acquisitions, as well as the marketing of investment offerings. Under his leadership, National Bank Financial developed notable expertise in tax-shelter financings. Retired since 1997, Mr. Pommier acts as a director of various companies. Mr. Pommier holds an MBA degree.
Rosconi, Yves Yves Rosconi, B. Sc. Pharm. MBA., is President, Chief Executive Officer, Director of Theratechnologies, Inc. Mr. Yves Rosconi, brings more than twenty five years of global pharmaceutical experience to Theratechnologies. He began his career with Abbott Laboratories and went on to spend twenty one years with Rhône-Poulenc Rorer in Canada and Australia with increasing responsibilities, ultimately becoming President and General Manager of Canadian operations. After leaving Rhône-Poulenc Rorer, he spent the next two years as Chief Operating Officer of Æterna Laboratories before joining Parisbased Aventis as Senior Vice President, responsible for Africa and the Middle East.
Tanguay, Luc Mr. Luc Tanguay, M.Sc., CFA., is Chiref Financial Officer, Senior Executive Vice President, Director of Theratechnologies, Inc. Mr. Luc Tanguay has been active in the biotechnology industry for over fifteen years. As a member of senior management at Theratechnologies since 1996, he has contributed to the Company’s growth by facilitating access to public and private capital funding. A member of the Board of Directors since 1993, he has held various management positions since joining the Company. Prior to joining Theratechnologies, Mr. Tanguay had a career in investment banking at National Bank Financial Inc. where he helped several organizations establish themselves as public companies.
Colussi, Marie-Noel Ms. Marie-Noel Colussi CA., is Vice President - Finance of Theratechnologies, Inc. Ms. Marie-Noel Colussi is a graduate of Universite du Quebec a Montreal in business administration. Prior to joining Theratechnologies, Ms. Colussi worked for eight years with KPMG, a accounting firm. Ms. Colussi has acquired sound experience in accounting, auditing, control and taxation, particularly in research and development. She joined Theratechnologies in March 1997, and prior to her appointment as Vice President, Finance in February 2002, she successively held the positions of Director, Accounting and Internal Control as well as Controller.
Lafond, Jocelyn Mr. Jocelyn Lafond, LL.B., LL.M., is Vice President- Legal Affairs,Corporate Secretary of Theratechnologies, Inc. Mr. Lafond has fifteen years of experience in the fields of corporate and securities law. Mr. Lafond holds a law degree from Universite Laval and a Masters Degree in Law from the University of Toronto. He has been a member of the Barreau du Quebec since 1992. Prior to joining the Company in 2007, Mr. Lafond was a partner with the international law firm of Fasken Martineau DuMoulin, LLP.
Gilpin, Andrea Dr. Andrea Gilpin, Ph.D., MBA., is Vice President - Investor Relations and Communications of Theratechnologies, Inc. Prior to joining Theratechnologies in 2007, Dr. Gilpin was Director, Investor Relations at MethylGene Inc. and held various positions in biotech companies. Dr Gilpin has a Ph.D. (Genetics/Biochemistry) from the University of Toronto and an MBA from the Asper School of Business.
Perazzelli, Pierre Mr. Pierre Perazzelli, B. Sc., is Vice President - Pharmaceutical Development of Theratechnologies, Inc. A graduate of Universite Laval, Mr. Perazzelli has been working in the pharmaceutical manufacturing industry for over twenty years. Throughout his career, he has held various positions in large pharmaceutical companies, such as Bristol Myers Squibb and Abbott Laboratories. He was Director of the LAB Laboratory, a research centre specializing in pharmaceutical formulation. He is also experienced in the production of generic drugs. Mr. Perazzelli joined Theratechnologies in May 2000.
Ortega, Martine Ms. Martine Ortega, Pharm. D. is Vice President - Compliance and Regulatory Affairs of Theratechnologies, Inc. Ms. Martine Ortega joined Theratechnologies in 2006. A graduate in pharmacy from the Université d’Aix-Marseille II, she holds a postdoctoral degree in dermatology. Ms. Ortega has close to twenty years of experience in the pharmaceutical industry where she has gained sound knowledge of the drug development process. During her career, she has acquired broad expertise in GLP, GCP and cGMP practices and procedures as well as in computerized systems validation. She is also experienced in relations with US, European and Canadian regulatory agencies. Before joining Theratechnologies, she held senior management positions at Ventana Clinical Research Corporation in Toronto, as well as MDS Pharma Services and at the Canadian subsidiary of Sandoz in Montreal.
Marsolais, Christian Dr. Christian Marsolais, Ph.D., is Vice President - Clinical Research and Medical Affairs of Theratechnologies, Inc. Dr. Christian Marsolais has over fifteen years of experience in clinical research for large pharmaceutical companies, such as Sandoz Canada and BioChem Therapeutics. Before joining Theratechnologies in 2007, Dr. Marsolais held various positions at Pfizer Global Pharmaceuticals, where he was appointed Director of Medical Affairs, Therapeutic Areas, in 2004. In this position, Dr. Marsolais was responsible of the clinical program and scientific initiatives development, as well as the integration of the Scientific Affairs and Clinical Research for the oncology and HIV Franchise. Dr. Marsolais holds a Ph.D. in Biochemistry from the Universite de Montreal.
Peri, Krishna Dr. Krishna Peri, Ph.D., is Vice President - Research of Theratechnologies, Inc. He is Co-inventor of the ExoPep technology and a founder of Pharma-G, Dr. Krishna Peri holds a Ph.D. in biochemistry from University of Saskatchewan, Canada. He pursued post-doctoral research in cancer as an NCI fellow at McGill University and at Ste. Justine Hospital Research Center. After the acquisition of Pharma-G by Theratechnologies in 2000, he served as director of discovery research, and was subsequently appointed Vice-President, Research, in June 2004.
Desrochers, Chantal Ms. Chantal Desrochers, B.Ph., MBA is Vice President - Business Development and Commercialisation of Theratechnologies, Inc. Ms. Chantal Desrochers obtained her degrees in pharmacy and business from the Universite de Montreal. She began her career at Schering-Plough in sales and ultimately became a Product Director. After obtaining her M.B.A., Ms. Desrochers joined Bristol-Myers Squibb Company in Canada as Marketing Director, Pharmaceuticals and became Vice President, Institutional Business in 1995. In 1997, Ms. Desrochers was promoted as European Franchise Marketing Director, Cardiovascular, in France where she implemented market penetration strategies and contributed to the commercial development of cardiovascular products. This led to her appointment as International Marketing Director, Cardiovascular, at Bristol-Myers Squibb in Princeton, New Jersey. Prior to joining Theratechnologies in 2005, Ms. Desrochers had been offering consulting services in business development and product development strategies.
De Grandpre, A. Jean A. Jean De Grandpre C.C., Q.C., is Corporate Director of Theratechnologies, Inc. He contributed to Bell Canada’s exceptional growth as Chairman of the Board and Chief Executive Officer and went on to become the founding Chairman of the Board and CEO of BCE. In recognition of these achievements, he was inducted into the Canadian Business Hall of Fame. Mr. de Grandpré also served as a member of the boards of directors of other important Canadian and US corporations, namely Northern Telecom Limited, Chrysler Corporation, Sun Life and TD Bank, and as a member of the international advisory boards of Chemical Bank and Goldman Sachs. He has been a member of the board of directors of Theratechnologies since its founding in October 1993 and was appointed Chairman in 1996. He resigned his position as Chairman in March 2007.
Talon, Jean-Denis Mr. Jean-Denis Talon is Director of Theratechnologies, Inc. He is Chairman of the Board, AXA Canada. Mr. Jean-Denis Talon had a successful career with AXA Insurance over a period of more than twenty years ultimately becoming President and Chief Executive Officer. He is currently Chairman of the Board of AXA Canada. Mr. Talon is also former President of the Financial Affairs Committee at the Insurance Bureau of Canada and a director of various companies.
Cloutier, Gilles Dr. Gilles Cloutier, Ph.D., is Corporate Director of Theratechnologies Inc. Dr. Gilles Cloutier has over thirty years of experience in the pharmaceutical industry including five years with contract research organizations, providing strategic support to the biotechnology and pharmaceutical industry. Dr. Cloutier has also held key positions with large North-American pharmaceutical companies where he developed expertise in the field of clinical research. His experience includes the development and approval of several drugs in Canada, the United States and Europe. Dr. Cloutier sits on the board of directors of Theratechnologies and is also Chairman of the Fondation André Delambre for amyotrophic lateral sclerosis (ALS).
Goyer, Robert Dr. Robert G. Goyer, Ph.D., is Director of Theratechnologies, Inc. He is Emeritus professor, Faculty of Pharmacy of the Universite de Montreal. Dr. Goyer has more that forty years of experience in the pharmaceutical field. Former President of Jouveinal Canada and of Clinipharm Inc., Dr. Goyer is also a former dean of the Faculty of Pharmacy of Université de Montréal. Recognized for his broad expertise in drug development, he has served on the boards of several companies and governmental organizations. He was notably Chairman of the Advisory Committee on drug approval procedures of Health Canada's Therapeutic Products Directorate and a member of the board of directors of the Régie de l’assurance maladie du Quebec. Most recently, he was Chairman of the Conseil du medicament (Quebec).
Reculeau, Bernard Mr. Bernard Reculeau is Director of Theratechnologies, Inc. He is President, CIS Bio International. Mr. Bernard Reculeau brings twenty-one years of pharmaceutical industry experience to Theratechnologies. Until recently, he was Senior Vice President Pharmaceutical Operations of Paris-based Sanofi-Aventis for the InterContinental Region. In his previous functions, he was responsible for product development and commercialization in numerous countries around the world. Mr. Reculeau has extensive hands-on management experience in commercial activities, cumulating close to fifteen years in pharmaceutical operations, notably in France where he very successfully ran the pharmaceutical operations for Rhône-Poulenc and Rhône-Poulenc Rorer as well as in many other countries of the European Union. Since September 19, 2006, he is President of a French company specializing in biomedical technologies.
Lacoste, Gerald Mr. Gerald A. Lacoste Q. C., is Corporate Director of Theratechnologies, Inc. He is a lawyer with extensive experience in the fields of securities regulation, financing and corporate governance. He was previously Chairman of the Quebec Securities Commission (now known as the Autorité des marchés financiers) and was also President and CEO of the Montreal Stock Exchange. During his career, Mr. Lacoste acted as legal counsel to the Canadian Standing Senate Committee on Banking, Trade and Commerce, he chaired the Quebec Advisory Committee on Financial Institutions, and was a member of the task force on the capitalization of life insurance companies in Quebec. Mr. Lacoste is currently a corporate director, actively involved in the biotechnology industry, and is a member of the North American Free Trade Agreement (NAFTA) arbitration panel.

Options Compensation

Name Options Value
Pommier, Paul 0 0
Rosconi, Yves 491,668 1,646,664
Tanguay, Luc 815,000 1,444,500
Colussi, Marie-Noel 0 0
Lafond, Jocelyn 0 0
Gilpin, Andrea 0 0
Perazzelli, Pierre 0 0
Ortega, Martine 86,000 4,749
Marsolais, Christian 51,000 0
Peri, Krishna 125,000 99,500
Desrochers, Chantal 115,000 253,975
De Grandpre, A. Jean 0 0
Talon, Jean-Denis 0 0
Cloutier, Gilles 0 0
Goyer, Robert 0 0
Reculeau, Bernard 0 0
Lacoste, Gerald 0 0

Insider Trading

» Full list on Insider Trading
view people for: